| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
IC50: 1.6 μM (Skeletal muscle myosin), 5.4 μM (Cardiac muscle myosin), and >100 μM (Smooth muscle myosin II)[1]
JB062 targets nonmuscle myosin, a motor protein involved in cellular processes such as cytokinesis, cell migration, and muscle contraction. As a myosin inhibitor, it exhibits differential activity across myosin isoforms, with potent inhibition of skeletal muscle myosin (IC50 = 1.6 µM) and cardiac muscle myosin (IC50 = 5.4 µM), but minimal effect on smooth muscle myosin II (IC50 >100 µM). By blocking myosin motor activity, JB062 interferes with actin-myosin interactions, which is crucial for understanding muscle physiology and related disorders. |
|---|---|
| ln Vitro |
In COS-7 cells, JB062 (compound 6b; 40 μM; 24 h) suppresses cytokinesis [1]. JB062 (COS-7 cells) has a CC10 value of 36 μM and is cytotoxic to human cancer cells but not normal cells [1].
In vitro, JB062 (40 µM; 24 hours) inhibits cytokinesis in COS-7 cells. The compound demonstrates selective cytotoxicity towards human cancer cells while showing no cytotoxic effects on normal cells. This selectivity profile makes JB062 a promising tool for studying cancer cell biology and developing targeted anti-cancer therapies. The compound's ability to discriminate between cancerous and non-cancerous cells suggests a potential therapeutic window for myosin inhibition in oncology. |
| ln Vivo |
In vivo data for JB062 is not extensively reported in publicly available sources. As a nonmuscle myosin inhibitor with selective cancer cell cytotoxicity, the compound is expected to have potential applications in animal models of cancer and muscle-related disorders. However, specific published in vivo efficacy studies are not detailed in the current literature. JB062 is primarily used as a research tool for studying myosin function, cytoskeletal dynamics, and cancer cell biology, with further in vivo studies needed to validate its therapeutic potential.
|
| Enzyme Assay |
The in vitro myosin inhibition assay for JB062 typically uses purified myosin isoforms (skeletal, cardiac, and smooth muscle) and measures ATPase activity in the presence of varying compound concentrations. The ATPase activity is detected using colorimetric or luminescent methods, and IC50 values are calculated from dose-response curves. Cytotoxicity assays are performed in cancer cell lines and normal cell lines using standard cell viability assays such as MTT or CellTiter-Glo, with treatment durations of 24-72 hours.
|
| Cell Assay |
Cellular assays for JB062 are conducted in COS-7 cells and various cancer cell lines. Cells are treated with JB062 at concentrations up to 40 µM for 24 hours. Cytokinesis is assessed by microscopy to determine the proportion of multinucleated cells. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo to assess cytotoxicity against cancer cells versus normal cells. The compound's effects on cell morphology and cytoskeletal organization may also be evaluated.
|
| Animal Protocol |
In vivo studies for JB062 would typically involve animal models of cancer, muscle spasticity, or hypertrophic cardiomyopathy. The compound would be administered via intraperitoneal or oral routes at doses determined by pharmacokinetic studies. Efficacy would be assessed by measuring tumor growth inhibition for cancer models or functional outcomes for muscle-related disorders. However, specific published in vivo protocols for JB062 are not available in the current literature. The compound is currently used as a research tool for studying myosin function.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for JB062 is not extensively reported in publicly available sources. The compound has a molecular weight of 319.35 g/mol and a molecular formula of C19H17NO4. As a small molecule myosin inhibitor, it is expected to have moderate oral bioavailability. Storage conditions: powder at -20°C for 3 years or 4°C for 2 years. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not available in the current literature for this research compound.
|
| Toxicity/Toxicokinetics |
Toxicity data for JB062 is derived from in vitro cytotoxicity studies showing selective cytotoxicity towards cancer cells with no effect on normal cells. As with all research compounds, JB062 is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays in normal cell lines and in vivo tolerability studies would be required for a complete toxicity assessment. The compound's selectivity for cancer cells suggests a favorable safety profile.
|
| References | |
| Additional Infomation |
JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6 µM, 5.4 µM, and >100 µM against skeletal, cardiac, and smooth muscle myosin II, respectively. It selectively exhibits cytotoxicity towards human cancer cells without affecting normal cells. JB062 is used in research on muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy. Its molecular formula is C19H17NO4. The compound serves as a valuable tool for studying myosin function, cytoskeletal dynamics, and cancer cell biology.
|
| Molecular Formula |
C19H17NO4
|
|---|---|
| Molecular Weight |
323.342585325241
|
| Exact Mass |
323.115
|
| CAS # |
2417988-00-0
|
| PubChem CID |
146020961
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
532
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=C(C(=O)OC2=CC=CC=C12)/C(/C)=N/CC1C=CC(OC)=CC=1
|
| InChi Key |
VNZQIXKYYHQDBZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H17NO4/c1-12(20-11-13-7-9-14(23-2)10-8-13)17-18(21)15-5-3-4-6-16(15)24-19(17)22/h3-10,21H,11H2,1-2H3
|
| Chemical Name |
4-hydroxy-3-[N-[(4-methoxyphenyl)methyl]-C-methylcarbonimidoyl]chromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0927 mL | 15.4636 mL | 30.9272 mL | |
| 5 mM | 0.6185 mL | 3.0927 mL | 6.1854 mL | |
| 10 mM | 0.3093 mL | 1.5464 mL | 3.0927 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
